Abstract
Radionuclide therapy targeting prostate-specific membrane antigen (PSMA) is a promising treatment for prostate cancer. We reported a ligand featuring two lysine-ureido-glutamate groups, 64Cu-CuSarbisPSMA previously. Here, we report the therapeutic potential of 67Cu-CuSarbisPSMA. Methods: Growth of PSMA-positive xenografts was evaluated following treatment with 67Cu-CuSarbisPSMA or 177Lu-LuPSMA I&T. Results: At 13 days post-injection, tumor growth was similarly inhibited by the two tracers in a dose-dependent manner. Survival was comparable after single (30 MBq) or fractionated administrations (2 x 15MBq, two weeks apart). Conclusion: 67Cu-CuSarbisPSMA is efficacious in a PSMA-expressing model of prostate cancer.
- Peptides
- Radiochemistry
- Radiopharmaceuticals
- copper-64
- copper-67
- prostate cancer
- prostate specific membrane antigen
- theranostics
- Copyright © 2020 by the Society of Nuclear Medicine and Molecular Imaging, Inc.